Search results for " pharmaceutical" in Articles / App Notes

Article Improving PAT for Biologics
Dec 01, 2014 By Cynthia Challener, PhD BioPharm International A key component of the quality-by-design (QbD) approach to pharmaceutical manufacturing is the implementation of process ana…

Article Biopharma Manufacturers Respond to Ebola Crisis
The agency also permitted Tekmira Pharmaceuticals (Vancouver) to treat infected patients with its experimental RNA interference drug by converting a “full clinical hold” to a “partial hold” on a Phase…

Article Single-Use and Continuous Processing Technologies Change Facility Design
In parallel, another change on the horizon in biopharmaceutical plants is continuous processing--the impact of which could be as significant in the pharmaceutical industry as it was in the car and ele…

Article Challenges in Analytical Method Development and Validation
According to Yong Guo, professor of pharmaceutical sciences at the School of Pharmacy, Fairleigh Dickinson University (FDU), analytical development and cross-functional development teams should work t…

Article Q&As with Industry Leaders
…echanistic Modeling in Process Development for Advanced Therapeutics  Felicity Thomas, Pharmaceutical Technology Europe Peter Guterstam, Product Manager, Advanced Therapeutics Downstre…

Article Biopharma Takes a Nervous Glance Over Its Shoulder
Biopharmaceutical Industry: Perspectives on Future Growth and The Factors That Will Drive It, published by Battelle and the Pharmaceutical Research and Manufacturers Association or PhRMA. The conclusi…

Article The Affordable Care Act's Impact on Innovation in Biopharma
The consolidation of hospitals into fewer, larger systems increases the leverage of buyers with all suppliers, including pharmaceutical companies. Beyond that, the integration of insurers with deliver…

Article Report from the Eighth International Plasma Product Biotechnology Meeting Melia Salinas, Lanzarote, Spain
Julie Kim also pointed out how the plasma industry differs from the more traditional pharmaceutical industry in terms of raw material costs where this represents 57% of the cost for the plasma industr…

Article Elucidating Biosimilars Characterization
Rather than requiring full clinical trials, generic drug manufacturers are requested to demonstrate pharmaceutical equivalence to show that their medicine contains the same active pharmaceutical ingre…

Article Biosimilars Development and Supply: How Complex Can the Process Be?
For approximately every 5000 to 10,000 pharmaceutical and biologic discoveries in preclinical testing, only one is eventually commercialized (4). An even smaller number of these medicines are biologic…

Show All Results

Previous PageNext Page